Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omega-3 studies

This article was originally published in The Tan Sheet

Executive Summary

Finnish adults who ate fish less than once a week were 31% more likely to suffer mild to severe depressive symptoms than those who ate it more frequently, according to a study presented at the American Psychiatric Association's annual meeting in Chicago May 16. Antti Tanskanen, MD, University of Kuopio, Finland, et al., surveyed 3,403 adults about depressive symptoms and fish consumption frequency, leading researchers to conclude infrequent use could lead to low intake of omega-3 polyunsaturated fatty acids, increasing the risk of depression. An NIH-sponsored study examining the effectiveness of omega-3 fatty acids in treating major depression and bipolar disorder currently is recruiting patients (1"The Tan Sheet" March 20, p. 12)

You may also be interested in...



NCCAM Omega-3 Fatty Acids Study To Commence In April

The National Institutes of Health is sponsoring several clinical trials on omega-3 fatty acids, including one investigating their effect on major depression and bipolar disorder and another studying fatty acids' antiarrhythmic effects.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel